Navigation Links
BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
Date:7/28/2008

s peramivir are necessary."

Dr. Thomas J. Simon, BioCryst's Senior Medical Advisor, stated, "Peramivir has now been studied in over 550 patients, allowing us to develop an extensive library of clinical knowledge about this potential therapy. The Shionogi Phase II study findings contribute important new information about the safety and efficacy of peramivir in patients with acute uncomplicated influenza."

"We are encouraged by the positive results of this Phase II study testing a single dose of i.v. peramivir in the outpatient setting," stated Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "As recently announced, we have initiated a Phase II study of intramuscular peramivir in a similar setting as the Shionogi study, which will add further confirmation of this promising compound's role in addressing seasonal influenza."

In February 2007, BioCryst and Shionogi entered into an exclusive license agreement under which Shionogi obtained rights to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. In exchange, BioCryst received a $14 million up-front payment and may also receive future clinical event milestone payments (up to $21 million) and commercial event milestone payments (up to $95 million) in addition to double-digit (between 10 percent and 20 percent range) royalty payments on product sales of peramivir. BioCryst retains all rights to commercialize peramivir in North America, Europe, and other countries outside of Japan and Korea.

Earlier this month, BioCryst commenced a Phase II study of intra-muscular (i.m.) peramivir in the outpatient setting comparing a single 600 mg dose to placebo in the treatment of seasonal influenza. The dose was selected based upon an analysis of a Phase I study of a new, more concentrated 150 mg/ml formulation of i.m. peramivir, as well as prior studies of peramivir in patients with influenza. The Phase II study w
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
2. BioCryst Updates Peramivir Clinical Development Plan
3. BioCryst Provides Forodesine HCl Update
4. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
5. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
6. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
7. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... , HOFFMAN ESTATES, Ill. , Jan. 28 ... and Drug Administration (FDA) has given 510(k) marketing clearance to ... System. , The DYNA-LINK system features a next-generation stand-alone device ... system is a thoracolumbar plating system that features multiple types ...
... , INDIANAPOLIS , Jan. 28 , Double-digit revenue ... Q4 gross margin Company delivers Q4 earnings per share of ... EPS rises to $3.94 (reported) or $4.42 (pro forma non-GAAP) ... 2010 EPS guidance range reconfirmed at $4.65 to $4.85 ...
Cached Medicine Technology:Lilly Reports Fourth-Quarter and Full-Year 2009 Results 2Lilly Reports Fourth-Quarter and Full-Year 2009 Results 3Lilly Reports Fourth-Quarter and Full-Year 2009 Results 4Lilly Reports Fourth-Quarter and Full-Year 2009 Results 5Lilly Reports Fourth-Quarter and Full-Year 2009 Results 6Lilly Reports Fourth-Quarter and Full-Year 2009 Results 7Lilly Reports Fourth-Quarter and Full-Year 2009 Results 8Lilly Reports Fourth-Quarter and Full-Year 2009 Results 9Lilly Reports Fourth-Quarter and Full-Year 2009 Results 10Lilly Reports Fourth-Quarter and Full-Year 2009 Results 11Lilly Reports Fourth-Quarter and Full-Year 2009 Results 12Lilly Reports Fourth-Quarter and Full-Year 2009 Results 13Lilly Reports Fourth-Quarter and Full-Year 2009 Results 14Lilly Reports Fourth-Quarter and Full-Year 2009 Results 15Lilly Reports Fourth-Quarter and Full-Year 2009 Results 16Lilly Reports Fourth-Quarter and Full-Year 2009 Results 17Lilly Reports Fourth-Quarter and Full-Year 2009 Results 18Lilly Reports Fourth-Quarter and Full-Year 2009 Results 19Lilly Reports Fourth-Quarter and Full-Year 2009 Results 20Lilly Reports Fourth-Quarter and Full-Year 2009 Results 21Lilly Reports Fourth-Quarter and Full-Year 2009 Results 22Lilly Reports Fourth-Quarter and Full-Year 2009 Results 23Lilly Reports Fourth-Quarter and Full-Year 2009 Results 24Lilly Reports Fourth-Quarter and Full-Year 2009 Results 25Lilly Reports Fourth-Quarter and Full-Year 2009 Results 26Lilly Reports Fourth-Quarter and Full-Year 2009 Results 27Lilly Reports Fourth-Quarter and Full-Year 2009 Results 28
(Date:7/9/2014)... at the Perelman School of Medicine at the University ... Institute have received an $8 million grant from the ... photodynamic light therapy (PDT) in patients with malignant pleural ... often manifests itself in the lining of the lungs ... The grant will fund a clinical trial and additional ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... researchers have uncovered mutations in a cell-signaling pathway that ... may expand treatments for patients because drugs targeting some ... in clinical trials. , Reporting July 9 in ... including researchers at Washington University School of Medicine in ... tumors from 230 patients with lung adenocarcinoma. , "This ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
... rates began to rise again around 2000, researchers have been ... especially in the homosexual community. The rising numbers are a ... to increased awareness of the virus. A new study in ... each year in the last decade saw a startling increase ...
... clinicians with expertise in polypharmacy, caregiving and more ... a free conference examining Alzheimer,s disease. The ... join with the Greater Kentucky and Southern Indiana ... Journey: Alzheimer,s Disease and Caregiving" from 9 a.m. ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. 24 ... they have found changes in the chemistry of the brains ... at future risk for Alzheimer,s disease and other dementias. ... the disease, experts say finding ways to identify those at ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- Since 2010, ... available at all has risen dramatically, according to the U.S. ... drugs given by injection and used in hospitals to treat ... are putting patients at risk and compromising their care, experts ...
... The Food and Drug Administration has cleared a new ... of thousands of AIDS patients stricken with cryptococcosis, a fungal ... Kozel, professor of microbiology of the University of Nevada School ... (Immuno-Mycologics) of Oklahoma. The new, rapid blood test known ...
... of HIV have increased in Pakistan,s general population, ... to women and their children, according to an ... Florida scientist. The researchers raise concern that ... may serve as indication that the virus may ...
Cached Medicine News:Health News:Why HIV infection rates are on the rise 2Health News:UofL experts featured at free Alzheimer's disease conference Sept. 17 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 3Health News:Cancer Drug Shortages Getting Worse, FDA Says 2Health News:Cancer Drug Shortages Getting Worse, FDA Says 3Health News:FDA clears new IMMY and University of Nevada, Reno life-saving blood test 2Health News:Study of HIV increase in Pakistan could benefit other research 2
... ExTOL systems feature your choice of ... electrocardiographs, an easy-to-operate monitor and the ... exercise stress testing systems also feature ... point, pre-programmed or custom protocols, and ...
... w/ Remote/Controller. Includes Full Range ... Children. Multiple 20/20 slides. Polarized ... allows you to customize your slide choices. ... with Long Life. Variety of mounting options. ...
... Ultimate in Stability. ... stabilizer features superior arm ... in the clamp/turret mechanism. ... features the ultimate flexibility ...
... leader in beating heart bypass, comes the ... NS device is the first leap in ... of surgical revascularization.,The Starfish NS Heart Positioner ... Small Thoracotomy (MVST) procedure without CPB and ...
Medicine Products: